Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Common semaglutide side effects include nausea, vomiting, diarrhea, and constipation. These should get better with time.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy ® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight ...

European drug regulators approved the higher-dose version of Wegovy in February. Called Wegovy HD, the higher-dose drug helped participants in a study lose about 19% of their body weight, or almost 47 ...

The Food and Drug Administration (FDA) on Thursday approved a higher dose of the Wegovy weight loss drug. The manufacturer, ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

Wegovy HD’s approval came on the cusp of the drug’s patent expiry in India and China, which leaves it vulnerable to biosimilar competition in these regions.

Dr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian ...

Talk about semaglutide—the drug better known by brand names like Ozempic, Wegovy, and Rybelsus—is everywhere these days. But if you’re considering getting pregnant or want to use the med ...